Advertisement

Annals of Hematology

, Volume 96, Issue 9, pp 1591–1593 | Cite as

Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice

  • Pasquale NiscolaEmail author
  • Andrea Tendas
  • Elisabetta Abruzzese
  • Tommaso Caravita
  • Luca Cupelli
  • Marco Giovannini
  • Laura Scaramucci
  • Agostina Siniscalchi
  • Monika Malgorzata Trawinska
  • Paolo de Fabritiis
Letter to the Editor

Dear Editor,

Chronic myelomonocytic leukemia (CMML) is an aging-related clonal hematopoietic stem cell disorder, classified as myelodysplastic/myeloproliferative disorders [ 1]. Indeed, its disease phenotype usually combines myelodysplastic (MD) and myeloproliferative (MP) features. Therefore, other than a persistent peripheral monocytosis representing the hematological disease hallmark, several degrees of cytopenias by ineffective hematopoiesis and a high propensity to progress into acute myeloid leukemia (AML) may characterize its clinical heterogeneity and a quite variable prognosis [ 2]. Therefore, CMML deserves specific management [ 2], being the treatment approach to MD-CMML traditionally based on supportive measures to palliate cytopenias and manage the related clinical complications, such as those applied to low risk myelodysplastic syndromes, whereas cytoreduction by hydroxyurea in MP-CMML forms continues to represent the currently standard of care [ 2]. Allogeneic stem cell...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405CrossRefPubMedGoogle Scholar
  2. 2.
    Solary E, Itzykson R (2017) How I treat chronic myelomonocytic leukemia. BloodGoogle Scholar
  3. 3.
    Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G (2017) Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. doi: 10.1002/ajh.24735
  4. 4.
    Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M, Atem FD, Rossetti JM, Sahovic EA, Lister J (2011) Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 117(12):2690–2696CrossRefPubMedGoogle Scholar
  5. 5.
    Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, Girschikofsky M, Schreder M, Pfeilstocker M, Lang A, Sliwa T, Geissler D, Schlick K, Placher-Sorko G, Theiler G, Thaler J, Mitrovic M, Neureiter D, Valent P, Greil R (2014) Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res 38(4):475–483CrossRefPubMedGoogle Scholar
  6. 6.
    Fianchi L, Criscuolo M, Breccia M, Maurillo L, Salvi F, Musto P, Mansueto G, Gaidano G, Finelli C, Aloe-Spiriti A, Santini V, Greco M, Hohaus S, Leone G, Voso MT (2013) High rate of remissions in chronic myelomonocytic leukemia treated with 5- azacytidine: results of an Italian retrospective study. Leuk Lymphoma 54(3):658–661CrossRefPubMedGoogle Scholar
  7. 7.
    Adès L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, Maciejewski JP, Dreyfus F, List AF, Fenaux P, Komrokji RS (2013) Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 37(6):609–613CrossRefPubMedGoogle Scholar
  8. 8.
    Niscola P, Tendas A, Scaramucci L, Giovannini M, Piccioni D, de Fabritiis P (2014) Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy. Blood Res 49(1):65–66CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, Nomdedeu B, Arenillas L, Luño E, Xicoy B, Amigo ML, Valcarcel D, Nachtkamp K, Ambaglio I, Hildebrandt B, Lorenzo I, Cazzola M, Sanz G (2013) Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 121(15):3005–15Google Scholar
  10. 10.
    Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC (2015) List AF; MDS/MPN International Working Group. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood 125(12):1857–1865CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Pasquale Niscola
    • 1
    Email author
  • Andrea Tendas
    • 1
  • Elisabetta Abruzzese
    • 1
  • Tommaso Caravita
    • 1
  • Luca Cupelli
    • 1
  • Marco Giovannini
    • 1
  • Laura Scaramucci
    • 1
  • Agostina Siniscalchi
    • 1
  • Monika Malgorzata Trawinska
    • 1
  • Paolo de Fabritiis
    • 1
  1. 1.Haematology UnitS. Eugenio HospitalRomeItaly

Personalised recommendations